# Obinutuzumab in Chinese Real-world Patients With iNHL

> **NCT05968001** · — · NOT_YET_RECRUITING · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 400 (estimated)

## Conditions studied

- Lymphomas Non-Hodgkin's B-Cell

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT05968001
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-20
- **Primary completion:** 2024-12-30
- **Final completion:** 2026-07-20
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05968001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05968001, "Obinutuzumab in Chinese Real-world Patients With iNHL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05968001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*